Active substances
Amlodipine + Olmesartan
- SFDA 31
- US FDA 15
- US price lines 7
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BITENS | 20,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 49.75 | Generic · Prescription | AJA PHARMACEUTICAL INDUSTRIES | Valid |
| BITENS | 40,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 61.80 | Generic · Prescription | AJA PHARMACEUTICAL INDUSTRIES | Valid |
| BITENS | 40,10 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 64.55 | Generic · Prescription | AJA PHARMACEUTICAL INDUSTRIES | Valid |
| Erastapecs Co | 40,10 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 66.00 | Generic · Prescription | Apex Pharma | Valid |
| Erastapecs Co | 40,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 61.55 | Generic · Prescription | Apex Pharma | Valid |
| Erastapecs Co | 20,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 47.05 | Generic · Prescription | Apex Pharma | Valid |
| OLMIDIP 20/5 mg FILM COATED TABLET | 20,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 55.30 | Generic · Prescription | LABORATORIOS CINFA SA | Valid |
| OLMIDIP 40/10 mg FILM COATED TABLET | 40,10 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 71.75 | Generic · Prescription | LABORATORIOS CINFA SA | Valid |
| OLMIDIP 40/5 mg FILM COATED TABLET | 40,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 68.65 | Generic · Prescription | LABORATORIOS CINFA SA | Valid |
| Olcontro Plus | 20,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 30.75 | Generic · Prescription | Med City Pharma | Valid |
| Olcontro Plus | 40,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 40.20 | Generic · Prescription | Med City Pharma | Valid |
| Olmevasc | 40,10 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 66.00 | Generic · Prescription | Saudi Amarox | Valid |
| Olmevasc | 40,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 61.55 | Generic · Prescription | Saudi Amarox | Valid |
| Olmevasc | 20,10 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 57.95 | Generic · Prescription | Saudi Amarox | Valid |
| Olmevasc | 20,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 47.05 | Generic · Prescription | Saudi Amarox | Valid |
| Olmexa | 40,10 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 71.85 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Olmexa | 40,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 66.95 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Olmexa | 20,10 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 63.10 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Olmexa | 20,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 51.25 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Olneda | 20,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 54.90 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| Olneda | 20,10 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 67.60 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| Olneda | 40,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 71.75 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| Olneda | 40,10 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 77.00 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| SEVIKAR 20/10MG FILM COATED TABLET | 20,10 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 86.90 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| SEVIKAR 20/5MG FILM COATED TABLET | 20,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 70.60 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
6 more — full table
Indications — CHI Daman Drug Formulary
HYPERTENSION
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| AZOR | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | COSETTE | Prescription | 26 Sep 2007 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 10MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;40MG | tablet · oral | MACLEODS PHARMS | Prescription | 26 Oct 2016 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | AJANTA PHARMA LTD | Prescription | 28 Oct 2016 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | AUROBINDO PHARMA | Prescription | 15 May 2017 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | ALEMBIC | Prescription | 17 Jul 2017 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | ALKEM LABS LTD | Prescription | 14 Aug 2017 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | ZYDUS PHARMS | Prescription | 22 Sep 2017 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | MICRO LABS | Prescription | 2 Nov 2017 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | SCIEGEN PHARMS | Prescription | 3 Dec 2018 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | HETERO LABS LTD V | Prescription | 14 Feb 2025 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | TEVA PHARMS USA | Discontinued | 26 Oct 2016 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | TORRENT | Discontinued | 25 Nov 2016 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | JUBILANT GENERICS | Discontinued | 15 May 2017 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;20MG; EQ 10MG BASE;40MG | tablet · oral | GLENMARK PHARMS LTD | Discontinued | 5 Jul 2017 |
| AMLODIPINE AND OLMESARTAN MEDOXOMIL | EQ 5MG BASE;20MG; EQ 10MG BASE;20MG; EQ 5MG BASE;40MG; EQ 10MG BASE;40MG | tablet · oral | ACCORD HLTHCARE INC | Discontinued | 30 Aug 2018 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | AMLODIPINE-OLMESARTAN 10-20 MG | $0.24767 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-OLMESARTAN 10-40 MG | $0.29874 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-OLMESARTAN 5-20 MG | $0.21854 | per EA | 23 Sep 2026 |
| US NADAC | AMLODIPINE-OLMESARTAN 5-40 MG | $0.31873 | per EA | 23 Sep 2026 |
| US NADAC | AZOR 10-40 MG TABLET | $19.53822 | per EA | 1 Jul 2026 |
| US NADAC | AZOR 5-20 MG TABLET | $15.32433 | per EA | 1 Jul 2026 |
| US NADAC | AZOR 5-40 MG TABLET | $19.63458 | per EA | 1 Jul 2026 |
| NHS Drug Tariff | Olmesartan medoxomil 20mg / Amlodipine 5mg tablets | £16.95 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.